Tango Therapeutics (NASDAQ:TNGX) reported fourth-quarter financial results on Thursday that surpassed Wall Street’s bottom-line expectations, supported by a significant extension of its capital reserves.
The Boston-based biotechnology firm, specializing in precision oncology through synthetic lethality, posted a net loss of $38.7 million for the quarter.
On a per-share basis, the loss was 29 cents, outperforming the 31-cent loss anticipated by analysts surveyed by Zacks Investment Research.
Full-year revenue for 2025 reached $62.4 million, a sharp increase from $30.0 million in 2024, primarily driven by the recognition of deferred revenue from its truncated Gilead collaboration.
For the year, the company reported a net loss of $101.6 million, or 87 cents per share, compared to a loss of $130.3 million in the previous year.
Tango bolstered its balance sheet to end the year with $343.1 million in cash and marketable securities, providing a clear operational runway into 2028 as it prepares to launch a pivotal Phase 3 study for its lead candidate, vopimetostat, in pancreatic cancer later this year.